Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 2

Conditions

Hypertension 3Diabetes Mellitus, Type 2 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1

Interventions

relacorilant 3Osilodrostat 3Metyrapone 2Radiofrequency Ablation 1ASP3662 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ACTH Syndrome, Ectopic × relacorilant × 1 year × Clear all
NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT04308590 2025-09-04

GRADIENT

Corcept Therapeutics

Phase 3 Completed
137 enrolled 25 charts

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension

NCT03697109 2025-07-16

GRACE

Corcept Therapeutics

Phase 3 Completed
152 enrolled 28 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡